PROFILPELAJAR.COM

Erteberel
Clinical data
Other names	Selective estrogen receptor beta agonist-1; SERBA-1; LY-500307; (3aS,4R,9bR)-1,2,3,3a,4,9b-Hexahydro-4-(4-hydroxyphenyl)cyclopenta(c)(1)benzopyran-8-ol; (2R,3S,4R)-SERBA
Routes of; administration	By mouth
Identifiers
	IUPAC name (3aS,4R,9bR)-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol;
CAS Number	533884-09-2;
PubChem CID	10286159;
DrugBank	DB07933;
ChemSpider	8461628;
UNII	2ZUL6758TZ;
KEGG	D09899;
ChEBI	CHEBI:231600;
ChEMBL	ChEMBL278703;
CompTox Dashboard (EPA)	DTXSID70201547 ;
Chemical and physical data
Formula	C18H18O3
Molar mass	282.339 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O;
	InChI InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1; Key:XIESSJVMWNJCGZ-VKJFTORMSA-N;

Erteberel (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code name LY-500307; also known as selective estrogen receptor beta agonist-1 or SERBA-1) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and was under development by Eli Lilly for the treatment of schizophrenia.^[2]^[3]^[4] It was specifically under investigation for the treatment of negative symptoms and cognitive impairment associated with the condition.^[2] It managed to reach phase II clinical trials for this indication in the United States in 2015.^[2] As of 2021 development has been discontinued.^[5] Erteberel was also under investigation for the treatment of benign prostatic hyperplasia and reached phase II clinical studies for this use but failed to improve symptoms in men with the condition and development for this indication was discontinued.^[2]^[6] The drug has also been proposed as a potential novel treatment for glioblastoma.^[7]

Erteberel has 14-fold binding selectivity for the ERβ over the ERα (K_i = 0.19 nM versus 2.68 nM, respectively).^[3]^[8] However, it shows 32-fold functional selectivity for activation of the ERβ over the ERα (EC₅₀ = 0.66 nM versus 19.4 nM, respectively).^[8] It is roughly a full agonist of both the ERβ and ERα (E_max = 101% versus 94%, respectively).^[3]^[8] Although selective for the ERβ, erteberel loses its selectivity at high dosages and activates the ERα as well, producing effects such as suppression of gonadal testosterone production in men.^[9]

References

^ Paterni I, Bertini S, Granchi C, Macchia M, Minutolo F (2013). "Estrogen receptor ligands: a patent review update". Expert Opin Ther Pat. 23 (10): 1247–71. doi:10.1517/13543776.2013.805206. PMID 23713677. S2CID 6259593.
^ ^a ^b ^c ^d "Erteberel - AdisInsight". adisinsight.springer.com. Archived from the original on 31 December 2016. Retrieved 22 May 2022.
^ ^a ^b ^c Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA (2011). "Estrogen receptor β ligands: recent advances and biomedical applications". Med Res Rev. 31 (3): 364–442. doi:10.1002/med.20186. PMID 19967775. S2CID 3841877.
^ Nilsson S, Koehler KF, Gustafsson JÅ (2011). "Development of subtype-selective oestrogen receptor-based therapeutics". Nat Rev Drug Discov. 10 (10): 778–92. doi:10.1038/nrd3551. PMID 21921919. S2CID 23043739.
^ "Erteberel - Eli Lilly and Company - AdisInsight".
^ Roehrborn CG, Spann ME, Myers SL, Serviss CR, Hu L, Jin Y (2015). "Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy". Prostate Cancer Prostatic Dis. 18 (1): 43–8. doi:10.1038/pcan.2014.43. PMID 25348255. S2CID 9315809.
^ Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK (2016). "Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma". Sci Rep. 6: 24185. Bibcode:2016NatSR...624185S. doi:10.1038/srep24185. PMC 4850367. PMID 27126081.
^ ^a ^b ^c Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA, Chen K, Wang Y, Durst GL, Barr RJ, Montrose-Rafizadeh C, Osborne HE, Amos RM, Guo S, Boodhoo A, Krishnan V (2006). "Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia". J. Med. Chem. 49 (21): 6155–7. doi:10.1021/jm060491j. PMID 17034120.
^ Hu L, Jin Y, Li YG, Borel A (2015). "Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men". Clinical Pharmacology in Drug Development. 4 (4): 305–14. doi:10.1002/cpdd.184. PMID 27136911. S2CID 21086262.